OBI Pharma, Inc. (TPEX:4174)
Taiwan · Delayed Price · Currency is TWD 38.55
+0.15 (0.39%)
At close: Mar 24, 2026
OBI Pharma Revenue
In the year 2025, OBI Pharma had annual revenue of 58.58M TWD, down -6.55%. OBI Pharma had revenue of 20.84M in the quarter ending December 31, 2025, with 80.44% growth.
Revenue
58.58M
Revenue Growth
-6.55%
P/S Ratio
86.20
Revenue / Employee
n/a
Employees
n/a
Market Cap
5.05B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 58.58M | -4.10M | -6.55% |
| Dec 31, 2024 | 62.68M | 21.13M | 50.85% |
| Dec 31, 2023 | 41.55M | 36.84M | 781.96% |
| Dec 31, 2022 | 4.71M | -14.06M | -74.90% |
| Dec 31, 2021 | 18.77M | -122.11M | -86.68% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sinphar Pharmaceutical | 3.37B |
| Panion & Bf Biotech | 2.06B |
| Medigen Biotechnology | 1.58B |
| BioGend Therapeutics | 222.34M |
| Pharmosa Biopharm | 67.27M |
| UnicoCell Biomed | 30.10M |
| AnnJi Pharmaceutical | 23.85M |
| Locus Cell | 5.18M |